REFERENCES
1. Hellings PW, Borrelli D, Pietikainen S, et al. European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017). Clin Transl Allergy. 2017;7:49.
2. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102(4 Pt 1):558-562.
3. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis.Cochrane Database Syst Rev. 2007(1):CD001936.
4. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1-55.
5. Wise SK, Schlosser RJ. Subcutaneous and sublingual immunotherapy for allergic rhinitis: what is the evidence? Am J Rhinol Allergy.2012;26(1):18-22.
6. Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124(5):997-1002.
7. Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129(1):128-135.
8. Jutel M, Akdis CA. Novel immunotherapy vaccine development.Curr Opin Allergy Clin Immunol. 2014;14(6):557-563.
9. Kundig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014;133(3):930-931.
10. Soyka MB, van de Veen W, Holzmann D, Akdis M, Akdis CA. Scientific foundations of allergen-specific immunotherapy for allergic disease.Chest. 2014;146(5):1347-1357.
11. Kundig TM, Klimek L, Schendzielorz P, Renner WA, Senti G, Bachmann MF. Is The Allergen Really Needed in Allergy Immunotherapy? Curr Treat Options Allergy. 2015;2(1):72-82.
12. Bachmann MF, Kundig TM. Allergen-specific immunotherapy: is it vaccination against toxins after all? Allergy. 2017;72(1):13-23.
13. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117(5):1021-1035.
14. Kariyawasam HK, Rotiroti G, Robinson DS. Sublingual immunotherapy in allergic rhinitis: indications, efficacy and safety. Rhinology.2013;51(1):9-17.
15. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468-475.
16. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001;31(9):1392-1397.
17. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy.2002;57(4):306-312.
18. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol.2002;109(2):251-256.
19. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943-948.
20. Basomba A, Tabar AI, de Rojas DH, et al. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol. 2002;109(6):943-948.
21. Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev.2009;61(3):256-262.
22. Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy.2009;39(4):562-570.
23. Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy. 2011;41(9):1305-1312.
24. Leuthard DS, Duda A, Freiberger SN, et al. Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling. J Immunol. 2018;200(9):3151-3159.
25. Zubeldia JM, Ferrer M, Davila I, Justicia JL. Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response. J Investig Allergol Clin Immunol. 2019;29(2):103-111.
26. Kundig TM, Senti G, Schnetzler G, et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults.J Allergy Clin Immunol. 2006;117(6):1470-1476.
27. Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy.J Allergy Clin Immunol. 2011;127(1):89-97, 97 e81-14.
28. Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131(1):103-109 e101-107.
29. Focke-Tejkl M, Weber M, Niespodziana K, et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol.2015;135(5):1207-1207 e1201-1211.
30. Schmitz N, Dietmeier K, Bauer M, et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med.2009;206(9):1941-1955.
31. Engeroff P, Caviezel F, Storni F, Thoms F, Vogel M, Bachmann MF. Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells. Allergy. 2018;73(2):341-349.
32. Shamji MH, Valenta R, Jardetzky T, et al. The role of allergen-specific IgE, IgG and IgA in allergic disease. Allergy.2021.
33. Celebi Sozener Z, Mungan D, Cevhertas L, Ogulur I, Akdis M, Akdis C. Tolerance mechanisms in allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2020;20(6):591-601.
34. Orengo JM, Radin AR, Kamat V, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.Nat Commun. 2018;9(1):1421.
35. Nakagome K, Nagata M. Allergen Immunotherapy in Asthma.Pathogens. 2021;10(11).
36. Bachmann MF, Mohsen MO, Kramer MF, Heath MD. Vaccination against Allergy: A Paradigm Shift? Trends Mol Med. 2020;26(4):357-368.
37. Zha L, Leoratti FMS, He L, et al. An unexpected protective role of low-affinity allergen-specific IgG through the inhibitory receptor FcgammaRIIb. J Allergy Clin Immunol. 2018;142(5):1529-1536 e1526.
38. Thoms F, Jennings GT, Maudrich M, et al. Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. J Allergy Clin Immunol.2019;144(1):193-203.
39. Beerli RR, Bauer M, Buser RB, et al. Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A.2008;105(38):14336-14341.
40. Uermosi C, Beerli RR, Bauer M, et al. Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol.2010;126(2):375-383.
41. Uermosi C, Zabel F, Manolova V, et al. IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. Allergy. 2014;69(3):338-347.
42. Petersen RL. Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development. Biosensors (Basel). 2017;7(4).
43. Ngkelo A, Richart A, Kirk JA, et al. Mast cells regulate myofilament calcium sensitization and heart function after myocardial infarction.J Exp Med. 2016;213(7):1353-1374.
44. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S73-80.
45. Cildir G, Pant H, Lopez AF, Tergaonkar V. The transcriptional program, functional heterogeneity, and clinical targeting of mast cells.J Exp Med. 2017;214(9):2491-2506.
46. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy.J Allergy Clin Immunol. 2007;119(4):780-791.
47. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited.Curr Opin Allergy Clin Immunol. 2004;4(4):313-318.
48. Nittner-Marszalska M, Malolepszy J, Zak-Nejmark T. [Skin tests, total IgE and venom specific IgE and IgG4 in serum of bee-keepers].Pneumonol Alergol Pol. 1993;61(7-8):342-345.
49. Varga EM, Kausar F, Aberer W, et al. Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol. 2013;131(5):1419-1421.
50. Engeroff P, Caviezel F, Storni F, Thoms F, Vogel M, Bachmann MF. Allergens displayed on virus-like particles are highly immunogenic but fail to activate human mast cells. Allergy. 2017.
Table 1: Kinetic parameters for the IgG1/IgG4 – CD32b interaction calculated by BLI